

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTApplicant **Lau et al**

(Use several sheets if necessary)

Filing Date **November 13, 2003**Group **To Be Assigned**

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,880,139	03/09/99	L.L. Chang	514	326	11/17/97
	5,776,954	07/07/98	de Laszlo et al	514	340	10/30/96
	4,359,474	11/16/82	Anderson et al	424	273	11/28/80
	4,374,130	02/15/83	Barcza	424	184	02/15/83
	5,837,719	11/17/98	de Laszlo et al	514	343	08/08/96
	6,503,949	01/2003	Lau et al.	514	617	

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO
<del>WO 00/39088</del>	<del>06/07/00</del>	<del>WIPO</del>	<del>---</del>	<del>---</del>		
<del>WO 94/14426</del>	<del>07/07/94</del>	<del>WIPO</del>	<del>---</del>	<del>---</del>		
<del>WO 98/04528</del>	<del>05/02/98</del>	<del>WIPO</del>	<del>---</del>	<del>---</del>		
<del>WO 98/21957</del>	<del>28/05/98</del>	<del>WIPO</del>	<del>---</del>	<del>---</del>		
WO 00/69810	23/11/00	WIPO	---	---	X	

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C.L. Brand et al., "Immunoneutralization of endogenous glucagons with Monoclonal glucagons antibody normalizes hyperglycaemia in moderately Streptozotocin-diabetic rats" *Diabetologia*, Vol. 37 pgs. 985-993 (1994)

C.L. Brand et al [535] *Diabetes* 43, [suppl 1], 172A (1994)

C.L. Brand et al., *Am J. Physiol.* 269, E469-E477 (1995)

C.L. Brand et al [492] *Diabetes* 44 [suppl 1], 134A (1995)

C.L. Brand et al., "Evidence for a Major Role for Glucagon in Regulation of Plasma Glucose in Conscious, Nondiabetic, and Alloxan Induced Diabetic Rabbits", *Diabetes* Vol. 45, pgs. 1076-1083 (1996)

L.J. Jelinek et al., "Expression Cloning and Signaling Properties of the Rat Glucagon Receptor" *Science* Vol. 259, pgs. 1614-1616 (1993)

EXAMINER

DATE CONSIDERED

2/3/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449  
(Rev. 2-32)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 6258.210-US

Serial No. To Be Assigned

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTApplicant  
Lau et al

(Use several sheets if necessary)

Filing Date November 13, 2003

Group To Be Assigned

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO
WO 98/22108	28/05/98	WIPO	—	—		
WO 98/22109	28/05/98	WIPO	—	—		
WO 99/01423	14/01/99	WIPO	—	—		
WO 98/24780	09/05/97	WIPO	—	—		

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

J.L. Collins et al., "CP-99, 711: A Non-Peptide Glucagon Receptor Antagonist" Bioorganic & Med.Chem.Ltr. Vol.2, No. 9, pgs. 915-918 (1992)
P. Madsen et al., "Discovery and Structure-Activity Relationship Of the First Non-Peptide Competitive Human Glucagon Receptor Antagonists" J.Med.Chem. Vo. 41, pages. 5150-5157 (1998)

EXAMINER

*Sam F. Stoddard*

DATE CONSIDERED

2/3/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

